Muljibhai Patel Urological Hospital International Honours For Dr. Mahesh Desai Of Mpuh Nadiad It Is A Matter Of Great Pride Not Just For The Muljibhai Patel Urological Hospital (mpuh), Nadiad, But The Country As A Whole, And The Indian Urology In Particular, That Dr. Mahesh Desai, Ms, Frcs (london), Frcs (edinburgh), Medical Director And Managing Trustee Of Mpuh, Has Been Elected As The ‘president-elect’ Of The Endourological Society Inc. At The World Congress Of Endourology (wce) Held At Kyoto, Japan During November 30 To December 3, 2011. During The Wce2011 At Kyoto, An Mpuh Doctor Won Two Prizes – 1st Prize For The Best Video “micro Percutaneous Nephrolithotomy: The Initial Feasibility Study”, And The 2nd Prize For The Best Essay “staghorn Morphometry: A New Tool For Clinical Classification And Prediction Model For Pcnl Monotherapy.” At The Initiative And Direction Of Dr. Mahesh Desai, Mpuh Had Successfully Organized The 12th World Video Urology Congress 2000 At Goa, And The 22nd World Congress On Endourology 2004 At Mumbai. It May Be Recalled, In October This Year, Dr. Mahesh Desai Had Become The First Indian To Assume The Office Of The President Of The Société Internationale D'urologie (siu) At The Siu World Congress Held At Berlin, Germany. It Is Unprecedented That Dr. Desai Is Perhaps The Only Person To Hold Both These Prestigious Positions Simultaneously Or Separately. The Other Positions That Dr Desai Has Held Include President, Urological Society Of India (2006-2007); Chairman, Sub-specialties, Society International D’urologie (siu) ( 2004-2009); Chairman, Scientific Committee, Endourology Society Inc. (2007 - Present); President, Asian Society Of Endourology (2008 - Present); Chairman, Endourology Education Training Site Committee Of Endourology Society Inc. (2008 - 2011); Member, International Committee Of American Urological Association (2008 - 2011). News Has Also Just Come In That Dr. Mahesh Desai Has Been Selected For The Prestigious ‘st. Paul’s Medal 2012’ By The British Association Of Urological Surgeons (baus). It Is Awarded To “distinguished Colleagues From Overseas Whose Contributions To The Association In Particular, Or To Urology In General, Baus Council Particularly Wishes To Appreciate And Honour.” Since The Inception Of This Medal In 1989, Dr. Mahesh Desai Is Only The Second Indian After Dr. Dara K Karanjavala (1993), To Be Honoured With This International Recognition. Www.mpuh.org

Be Cautious In Life You Are Answerablegod Won't Ask What Kind Of Education Degree You Have,but Will Ask How Many People You Taught Or Make Them Educated.god Won't Ask How Humble Soft You Describe Your Self ,but Will See How Humbly You Behave With Fellow Persons.god Won't Ask You How Wise And Diplomatic You Are,but How You Utilise These To Improve Humility And Humanity. God Won't Ask What Kind Of Car You Drove, But Will Ask How Many People You Drove Who Didn't Have Transportation. God Won't Ask The Square Footage Of Your House, But Will Ask How Many People You Welcomed Into Your Home.god Won't Ask About The Fancy Clothes You Had In Your Closet, But Will Ask How Many Of Those Clothes Helped The Needy.god Won't Ask About Your Social Status, But Will Ask What Kind Of Status You Raised To Down One Fellows.god Won't Ask How Many Material Possessions You Had, But Will Ask Whether You Utilised Them To Show Yourself. God Won't Ask What Your Highest Salary Was, But Will Ask If You Compromised Your Character To Obtain That Salary.god Won't Ask How Much Overtime You Worked, But Will Ask If You Worked Overtime For Your Family And Loved Ones. God Won't Ask How Many Promotions You Received, But Will Ask How You Promoted Others. God Won't Ask What Your Job Title Was, But Will Ask If You Reformed Your Job To The Best Of Your Ability.god Won't Ask What You Did To Help Yourself, But Will Ask What You Did To Help Others. God Won't Ask How Many Friends You Had, But Will Ask How Many People To Whom You Were A True Friend. God Won't Ask What You Did To Protect Your Rights, But Will Ask What You Did To Protect The Rights Of Others.god Won't Ask In What Neighborhood You Lived, But Will Ask How You Treated Your Neighbors. God Won't Ask About The Color Of Your Skin, But Will Ask About The Content Of Your Character. God Won't Ask How Many Times Your Deeds Matched Your Words, But Will Ask How Many Times They Didn't.god Won't Not Ask You How Strong Your Body Is,but Ask You How You Make Many Weak Persons Strong One.god Won't Ask You How Rich Wealty You Are,but How You Donate This Wealth To Welfare Down Trodden And Poors.god Won; Ask You How Popular Are You In Media,but Ask Your Popularity In Heart Of Common Man Living With You.so Be A Really A Good Man By Heart Not A Show Mandr.d.r.nakipuriaambika Chikitshalya29 Agrasen Road,siliguri-509434143550

Patients Must Be Told To Undertake Lifelong Art. Start Treatment For Symptomatic Patients Regardless Of Cd4 Cell Count. Start Drugs For Asymptomatic Individuals With Cd4 Cell Counts <500/l. Do Risk Reduction Counseling At Each Patient–clinician Interaction. Regimen: Consider Resistance–testing Results And Predicted Virologic Efficacy, Toxicity And Tolerability, Pill Burden, Dosing Frequency, Drug–drug Interactions, Comorbidities, Patient And Practitioner Preference, And Cost And Affordability. Combine Two Nucleoside Reverse Transcriptase Inhibitors And A Potent Third Agent From Another Class. Prefer A Fixed–dose Formulations And Once–daily Regimen. Suppress Hiv To Less Than 50 Copies/ml (polymerase Chain Reaction) Or 75 Copies/μl (branched Dna) By 24 Weeks. To Detect Failure: Repeat Testing Of Hiv–1 Rna 2 To 8 Weeks After Initiation, Every Four To Eight Weeks Until Suppressed, And Then Every 3 To 4 Months For At Least The First Year. Monitor Cd4 Cell Counts At Least Every 3 To 4 Months After Starting Therapy, Especially In Patients With Counts <200/μl, To Assess Whether Prophylaxis Is Needed For Opportunistic Infections. Do More Frequent Monitoring In Patients Who Have Changed Therapy Because Of Virologic Failure. Even If One Or More Regimens Have Failed, The Therapeutic Goal Should Still Be Undetectable Plasma Hiv–1 Rna Levels. Achieve This Goal With New Drugs And Regimens. If An Elevation In Viral Load Occurs After Complete Suppression Is Achieved, Consider Poor Adherence, Drug–drug Interactions, Concurrent Infections And Recent Vaccinations As Possible Causes Before Changing Regimens. Repeat Testing For An Isolated Detectable Viral Load To Exclude Errors Or Self–resolving Low–level Viremia. When Changing Regimens After First– Or Multiple–regimen Failure, Consider The Stage Of Hiv, Nadir And Current Cd4 Cell Count, Comorbidities, Treatment History, Current And Previous Drug Resistance Tests, And Drug Interactions. Include At Least Two Drugs, And Preferably Three Fully Active Drugs Or Drugs From New Classes. Single–agent Switches To Decrease Toxicity, Avoid Drug Interactions, Or Improve Convenience And Adherence Are Possible, Provided The Potency Of The Regimen Is Maintained And Drug Interactions Are Managed. Boosted Protease Inhibitor Monotherapy Is Not Recommended, Except When Other Drugs Raise Issues Of Toxicity Or Tolerability. Delaying Such Switches May Affect Adherence And Risk Development Of Resistance